Arcutis Biotherapeutics (ARQT) announced that it will present five posters at the 2025 Revolutionizing Atopic Dermatitis, RAD, Conference, which is taking place in Nashville, TN, from June 6-7, 2025. Importantly, the Company will present new data from its INTEGUMENT-OLE study demonstrating the long-term safety and durable efficacy of investigational ZORYVE cream 0.05% in children ages 2 to 5 with AD, consistent with previous studies. Starting at Week 4 of INTEGUMENT-OLE, participants who achieved a validated Investigator Global Assessment (vIGA-AD) score of clear, switched to proactive twice-weekly application. For participants who switched to twice-weekly application, the median duration of disease control was 238 days, consistent with the 281 days observed for adults and children down to age 6 who used twice-weekly dosing.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Buy Rating for Arcutis Biotherapeutics Driven by FDA Approval and Market Potential of Zoryve Foam
- Arcutis Biotherapeutics: Buy Rating Affirmed on FDA Approval and Promising Commercial Prospects for Zoryve Foam
- Arcutis Biotherapeutics: Buy Rating Affirmed on Strong FDA Approvals and Promising Pipeline
- Arcutis Biotherapeutics reports FDA approves sNDA for Zoryve topical foam
- Arcutis announces publication of Genital Psoriasis Wellness Consortium statement